- Home
- OKUR vs BEAT Comparison
OKUR vs BEAT Comparison
Compare OKUR & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- BEAT
- Stock Information
- Founded
- OKUR 2011
- BEAT 2015
- Country
- OKUR United States
- BEAT United States
- Employees
- OKUR N/A
- BEAT N/A
- Industry
- OKUR
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- OKUR
- BEAT Technology
- Exchange
- OKUR NYSE
- BEAT Nasdaq
- Market Cap
- OKUR 75.5M
- BEAT 74.1M
- IPO Year
- OKUR N/A
- BEAT 2021
- Fundamental
- Price
- OKUR $5.74
- BEAT $2.26
- Analyst Decision
- OKUR Strong Buy
- BEAT Buy
- Analyst Count
- OKUR 4
- BEAT 1
- Target Price
- OKUR $35.00
- BEAT $8.00
- AVG Volume (30 Days)
- OKUR 135.4K
- BEAT 110.4K
- Earning Date
- OKUR 02-14-2025
- BEAT 03-19-2025
- Dividend Yield
- OKUR N/A
- BEAT N/A
- EPS Growth
- OKUR N/A
- BEAT N/A
- EPS
- OKUR N/A
- BEAT N/A
- Revenue
- OKUR N/A
- BEAT N/A
- Revenue This Year
- OKUR N/A
- BEAT N/A
- Revenue Next Year
- OKUR N/A
- BEAT N/A
- P/E Ratio
- OKUR N/A
- BEAT N/A
- Revenue Growth
- OKUR N/A
- BEAT N/A
- 52 Week Low
- OKUR $4.58
- BEAT $1.35
- 52 Week High
- OKUR $20.00
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- BEAT 47.78
- Support Level
- OKUR N/A
- BEAT $2.02
- Resistance Level
- OKUR N/A
- BEAT $2.44
- Average True Range (ATR)
- OKUR 0.00
- BEAT 0.14
- MACD
- OKUR 0.00
- BEAT 0.04
- Stochastic Oscillator
- OKUR 0.00
- BEAT 50.00
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.